Aa biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Our proprietary targeted protein degradation platform, which we refer to as Pegasus, allows us to discover highly selective small molecule protein degraders with potent activity against disease-causing proteins throughout the body
Lead Underwriter
BofA Securities, Inc, Cowen and Company, LLC, Guggenheim Securities, LLC, Morgan Stanley & Co. LLC
